research update
-
Research updates, February 25
-
Research updates, February 18
-
Research updates, February 11
-
Research updates, February 4
-
Research updates, January 28
More research news
-
Research updates, January 21
The U.S. government is funding a $375 million effort for a new COVID-19 prevention drug for immunocompromised people, as part of Project NextGen. The federal health department provided the funds to the drug company Shionogi Inc. for a long-acting pre-exposure prophylactic (PreP) called S-892216 that blocks the main protease of SARS-CoV-2.
-
Research updates, January 14
-
Research updates, January 7
*Editor’s note: Julia Moore Vogel, an author of Paxlovid study, is on The Sick Times’ advisory board. Other authors are also affiliated with the Patient-Led Research Collaborative, which shares a funding source (the Balvi and Kanro funds) with The Sick Times. One author (JD Davids) is affiliated with Long COVID Justice, with which we collaborated…
-
Research updates, December 24
A 2020 paper that spread controversial claims about the anti-malarial drug hydroxychloroquine as a treatment for COVID-19 was retracted last week. Published in the International Journal of Antimicrobial Agents, the paper was pulled for ethical concerns and other methodological problems. Earlier in the pandemic, the paper led to shortages of the drug for people with…
-
Research updates, December 17
Editor’s note, December 19, 11am EST: The fourth summary has been updated to correct information about the patients who were autopsied. Related stories
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance